KRAS mutations in NSCLC can also enhance SREBP activity by activating the extracellular signal-regulated kinase (ERK) 1/2-mTORC1 pathway, which subsequently promotes FASN expression and increases fatty acid synthesis (24, 47). Here, KRAS is linked to non-small cell lung carcinoma.